-
公开(公告)号:US07419664B2
公开(公告)日:2008-09-02
申请号:US10855745
申请日:2004-05-27
IPC分类号: A61K39/395
CPC分类号: G01N33/6872 , A61K38/00 , A61K2039/505 , C07K14/47 , C07K16/28 , G01N2500/04
摘要: The invention relates to methods of treating a disease or condition, wherein expression or activity of soluble CLCA1 is up-regulated, by administering inhibitors of soluble CLCA1. The invention also relates to methods of isolating soluble CLCA1 from a bodily fluid.
摘要翻译: 本发明涉及通过施用可溶性CLCA1抑制剂来治疗疾病或病症的方法,其中可溶性CLCA1的表达或活性被上调。 本发明还涉及从体液中分离可溶性CLCA1的方法。
-
公开(公告)号:US20090214520A1
公开(公告)日:2009-08-27
申请号:US12222980
申请日:2008-08-21
IPC分类号: A61K39/395 , A61K38/02 , C07K1/00
CPC分类号: G01N33/6872 , A61K38/00 , A61K2039/505 , C07K14/47 , C07K16/28 , G01N2500/04
摘要: The invention relates to methods of treating a disease or condition, wherein expression or activity of soluble CLCA1 is up-regulated, by administering inhibitors of soluble CLCA1. The invention also relates to methods of isolating soluble CLCA1 from a bodily fluid.
摘要翻译: 本发明涉及通过施用可溶性CLCA1抑制剂来治疗疾病或病症的方法,其中可溶性CLCA1的表达或活性被上调。 本发明还涉及从体液中分离可溶性CLCA1的方法。
-
公开(公告)号:US20100227859A1
公开(公告)日:2010-09-09
申请号:US12598868
申请日:2008-05-05
申请人: Wei LI , Jianchang Li , Yuchuan Wu , Junjun Wu , Rajeev Hotchandani , Steve Yikkai Tam , Tarek Suhayl , Joseph P. Sypek , Iain McFadyen
发明人: Wei LI , Jianchang Li , Yuchuan Wu , Junjun Wu , Rajeev Hotchandani , Steve Yikkai Tam , Tarek Suhayl , Joseph P. Sypek , Iain McFadyen
IPC分类号: A61K31/5377 , C07D407/04 , A61K31/343 , C07D413/14 , C07D417/14 , A61K31/497 , A61P19/02 , A61P9/10 , A61P11/06 , A61P35/00 , A61P3/04 , A61P3/10
CPC分类号: C07D307/91 , C07D333/76 , C07D405/04 , C07D409/04 , C07D409/14 , C07D413/04 , C07D413/14 , C07D417/04 , C07D417/14
摘要: The present teachings relate to compounds of formula I: and pharmaceutically acceptable salts and esters thereof, wherein R1, R2, R3, R4, X, and Y are as defined herein. The present teachings also provide methods of making the compounds of formula I and methods of inhibiting matrix metalloproteinases, in particular, MMP-12, that may be involved in pathological disorders found in mammals, including a human.
摘要翻译: 本发明涉及式I化合物及其药学上可接受的盐和酯,其中R 1,R 2,R 3,R 4,X和Y如本文所定义。 本教导还提供制备式I化合物的方法和抑制基质金属蛋白酶特别是MMP-12的方法,所述方法可能涉及哺乳动物(包括人)中发现的病理学障碍。
-
-